Calif. company seeks approval for insulin inhaler

12/10/2013 | Los Angeles Times (tiered subscription model)

California-based pharmaceutical company MannKind is seeking government approval for a new form of insulin powder that can be inhaled instead of injected to treat both type 1 and type 2 diabetes. The drug, called Afrezza, has completed Phase III trials and is now under FDA review.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX